Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Regulatory News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.50
Bid: 9.50
Ask: 11.40
Change: 0.10 (1.06%)
Spread: 1.90 (20.00%)
Open: 9.20
High: 10.00
Low: 9.20
Prev. Close: 9.40
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

22 Aug 2019 11:42

RNS Number : 9401J
e-Therapeutics plc
22 August 2019
 

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

 

e-Therapeutics PLC

 

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

 

3. Full name of person(s) subject to the notification obligation: iii

Rupert Labrum

4. Full name of shareholder(s)

(if different from 3.): iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

16/08/2019

6. Date on which issuer notified:

20/08/2019

7. Threshold(s) that is/are crossed or reached: vi, vii

 

4.00%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

Situation previous to the triggering transaction

 

Resulting situation after the triggering transaction

 

if possible using

the ISIN CODE

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00B2823H99

 

12015000

 

12015000

 

12015000

 

12015000

 

4.46%

 

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial

Expiration

Exercise/

Number of voting

% of voting

instrument

date xiii

Conversion

rights that may be

rights

Period xiv

acquired if the

instrument is

exercised/

converted.

 

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights

xix, xx

Nominal

Delta

 

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1201500

4.46%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

 

 

 

 

 

 

 

 

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

 

 

13. Additional information:

14. Contact name:

Rupert Labrum

15. Contact telephone number:

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLEAEPAAAKNEFF
Date   Source Headline
21st Jun 201612:59 pmRNSIssue of Equity
7th Jun 20162:08 pmRNSIssue of Equity and Directors' shareholdings
1st Jun 20167:00 amRNSSearchbolt Offer becomes wholly unconditional
27th May 20163:18 pmRNSResult of General Meeting
25th May 20162:59 pmRNSResult of AGM
25th May 20167:00 amRNSAGM Statement
13th May 20164:08 pmRNSNotice of General Meeting - Correction
12th May 201610:50 amRNSDirector/PDMR Shareholding
11th May 20167:00 amRNSProposed Acquisition of Searchbolt, Notice of GM
15th Apr 201612:19 pmRNSNotice of AGM and Annual Report
22nd Mar 20167:00 amRNSFinal Results
4th Mar 20167:00 amRNSNotice of Results
15th Feb 20167:00 amRNSTop-line Phase IIb results update
6th Jan 20167:00 amRNSAppointment of Non-Executive Chairman
15th Dec 20153:38 pmRNSHolding(s) in Company
30th Nov 20154:48 pmRNSHolding(s) in Company
29th Oct 20157:00 amRNSAppointment of Non-Executive Director
29th Sep 20157:00 amRNSHalf Yearly Report
17th Sep 20157:05 amRNSNotice of Half Year Results
17th Sep 20157:00 amRNSChange of Nominated Adviser and Broker
10th Sep 20159:00 amRNSDirector's Disclosure
17th Aug 20157:00 amRNSHalf year trading and commercial strategy update
19th Jun 20158:38 amRNSExercise of Options
11th Jun 201511:31 amRNSResult of AGM
11th Jun 20157:00 amRNSAGM Statement
21st May 20157:00 amRNSProgress in ETS2101 Phase Ib Study
7th May 20157:00 amRNSNotice of AGM and Annual Report
31st Mar 20157:00 amRNSFinal Results
11th Mar 20154:08 pmRNSHolding(s) in Company
11th Mar 201512:41 pmRNSHolding(s) in Company
10th Mar 20157:03 amRNSNotice of Full Year Results
6th Mar 20152:22 pmRNSHolding(s) in Company
26th Feb 20151:55 pmRNSStmnt re Share Price Movement
21st Jan 201511:20 amRNSDirector/PDMR Shareholding
7th Jan 20157:00 amRNSAwards made under Performance Share Plan
7th Jan 20157:00 amRNSIssue of Equity
5th Jan 20157:00 amRNSDirectorate Change
19th Dec 20147:00 amRNSe-Therapeutics' Impact is rated World Class
18th Dec 20147:00 amRNSUpdate: ETS2101 Phase 1a and Oral Dosing Studies
27th Nov 20147:00 amRNSResearch and Development presentation to Investors
16th Oct 20148:35 amRNSAppointment of Executive Director
16th Sep 20147:00 amRNSHalf Yearly Report
4th Sep 20142:55 pmRNSNotice of Results
5th Aug 20147:00 amRNSAdditional Listing
1st Aug 20149:22 amRNSIssue of equity and Directors' shareholdings
9th Jul 201411:31 amRNSAGM Statement
9th Jul 20147:00 amRNSAwards made under Performance Share Plan
4th Jul 20147:00 amRNSDirector/PDMR Shareholding
27th Jun 20147:00 amRNSChange of Adviser
25th Jun 20144:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.